Products by development stage for any of 244 targets, every modality class and every cancer, with the phase 2 and 3 studies registered for them. Below, a crowding index: active assets per 100,000 addressable patients a year, currently led by KIT, MSH2, PALB2.
Registry counts are ClinicalTrials.gov phase 2 and 3 studies naming each product (fetched 2026-11-09); a combination study counts once per product it names, so sums overstate distinct trials.
KIT 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 12 | 3 | 2,493 | 1k (676 to 2k) | 1257.4* | |
MSH2 1 cancer with incidence and prevalence data | 1 | 0 | 0 | 7k (464 to 14k) | 97.36 | |
PALB2 4 cancers with incidence and prevalence data | 1 | 0 | 0 | 11k (4k to 17k) | 75.49 | |
mTOR 1 cancer with incidence and prevalence data | 3 | 1 | 1,819 | 12k (9k to 15k) | 50.87 | |
BCR::ABL1 (Philadelphia chromosome) 1 cancer with incidence and prevalence data | 8 | 0 | 538 | 19k (8k to 30k) | 47.21 | |
NTRK 6 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 4 | 0 | 53 | 14k (7k to 22k) | 34.75* | |
FLT3 1 cancer with incidence and prevalence data | 6 | 0 | 162 | 33k (21k to 45k) | 27.44 | |
Retinoic acid receptor alpha (RARA) 1 cancer with incidence and prevalence data | 2 | 0 | 116 | 12k (8k to 15k) | 25.78 | |
VEGF / VEGFR 1 cancer with incidence and prevalence data · partial: 2 without a GLOBOCAN estimate | 22 | 4 | 9,427 | 138k (100k to 177k) | 23.14* | |
FGFR2 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 8 | 4 | 1,165 | 66k (33k to 99k) | 22.76* | |
MET 5 cancers with incidence and prevalence data | 12 | 5 | 533 | 179k (110k to 248k) | 15.61 | |
MDM2 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 1 | 20 | 15k (15k to 15k) | 13.19* | |
KMT2A (MLL) rearrangement 2 cancers with incidence and prevalence data | 2 | 0 | 1,576 | 16k (6k to 25k) | 12.87 | |
LAG-3 1 cancer with incidence and prevalence data | 1 | 2 | 142 | 40k (25k to 54k) | 12.59 | |
CDK4/6 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 5 | 3 | 687 | 73k (36k to 110k) | 12.4* | |
RET 4 cancers with incidence and prevalence data | 8 | 1 | 1,063 | 89k (43k to 135k) | 12.31 | |
Topoisomerase II alpha (TOP2A) 1 cancer with incidence and prevalence data | 0 | 1 | 113 | 43k (26k to 60k) | 11.74 | |
BCMA 1 cancer with incidence and prevalence data | 8 | 2 | 212 | 177k (158k to 196k) | 11.28 | |
CD25 (IL-2 receptor alpha) 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 1 | 1 | 37 | 45k (42k to 49k) | 11.03* | |
ROS1 2 cancers with incidence and prevalence data | 6 | 0 | 140 | 57k (34k to 79k) | 10.6 | |
BTK (Bruton tyrosine kinase) 1 cancer with incidence and prevalence data | 5 | 3 | 768 | 85k (50k to 121k) | 10.54 | |
CD19 3 cancers with incidence and prevalence data | 12 | 4 | 381 | 334k (223k to 445k) | 9.87 | |
ALK 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 11 | 1 | 312 | 132k (78k to 187k) | 9.83* | |
EZH2 1 cancer with incidence and prevalence data · partial: 2 without a GLOBOCAN estimate | 1 | 1 | 66 | 42k (29k to 56k) | 9.41* | |
PDGFRA 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 1 | 15 | 22k (17k to 27k) | 9.24* | |
CD22 1 cancer with incidence and prevalence data | 1 | 0 | 62 | 68k (38k to 99k) | 8.77 | |
PRAME 1 cancer with incidence and prevalence data | 0 | 2 | 5 | 46k (24k to 68k) | 8.7 | |
Somatostatin receptor 2 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 6 | 3 | 188 | 135k (82k to 188k) | 8.14* | |
PARP 4 cancers with incidence and prevalence data | 6 | 2 | 695 | 259k (193k to 326k) | 8.1 | |
Menin 2 cancers with incidence and prevalence data | 2 | 0 | 19 | 39k (23k to 54k) | 7.73 | |
IDH1 / IDH2 4 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 7 | 3 | 101 | 134k (91k to 177k) | 7.44* | |
PD-1 2 cancers with incidence and prevalence data | 18 | 4 | 7,561 | 523k (263k to 784k) | 7.26 | |
BRCA1 / BRCA2 (HRD) 12 cancers with incidence and prevalence data | 7 | 0 | 497 | 213k (113k to 313k) | 7.05 | |
CD123 1 cancer with incidence and prevalence data | 2 | 0 | 16 | 89k (59k to 119k) | 6.75 | |
WEE1 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 1 | 7 | 45k (35k to 56k) | 6.6* | |
HER2 16 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 24 | 14 | 2,859 | 869k (499k to 1.2m) | 6.44* | |
CD20 2 cancers with incidence and prevalence data | 8 | 1 | 2,726 | 264k (181k to 346k) | 6.07 | |
ATM 3 cancers with incidence and prevalence data | 0 | 0 | 0 | 52k (21k to 83k) | 5.78 | |
AKT 3 cancers with incidence and prevalence data | 3 | 2 | 687 | 107k (54k to 160k) | 5.62 | |
Nectin-4 2 cancers with incidence and prevalence data | 1 | 0 | 89 | 183k (107k to 259k) | 5.47 | |
Claudin 18.2 2 cancers with incidence and prevalence data | 3 | 6 | 90 | 435k (274k to 597k) | 4.59 | |
CD33 1 cancer with incidence and prevalence data | 1 | 0 | 85 | 103k (72k to 134k) | 3.9 | |
Estrogen receptor (ERα) 2 cancers with incidence and prevalence data | 14 | 2 | 1,632 | 467k (283k to 652k) | 3.64 | |
NRAS 1 cancer with incidence and prevalence data | 1 | 0 | 1 | 60k (29k to 92k) | 3.32 | |
BRAF 10 cancers with incidence and prevalence data | 13 | 0 | 1,189 | 425k (225k to 625k) | 3.29 | |
Interleukin-6 and IL-6 receptor 1 cancer with incidence and prevalence data | 2 | 0 | 353 | 64k (58k to 69k) | 3.15 | |
GPRC5D 1 cancer with incidence and prevalence data | 1 | 1 | 30 | 128k (100k to 157k) | 3.11 | |
PD-L1 8 cancers with incidence and prevalence data | 12 | 10 | 2,209 | 998k (708k to 1.3m) | 3.01 | |
Androgen receptor 5 cancers with incidence and prevalence data | 9 | 1 | 1,004 | 547k (237k to 857k) | 2.74 | |
PSMA 3 cancers with incidence and prevalence data | 7 | 6 | 130 | 753k (461k to 1.0m) | 2.39 | |
CD52 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 1 | 0 | 264 | 85k (50k to 121k) | 2.34* | |
EGFR 12 cancers with incidence and prevalence data | 30 | 6 | 3,702 | 2.5m (1.6m to 3.5m) | 2.33 | |
CD38 2 cancers with incidence and prevalence data | 2 | 1 | 434 | 262k (209k to 315k) | 1.91 | |
TROP2 6 cancers with incidence and prevalence data | 3 | 4 | 331 | 1.8m (1.3m to 2.2m) | 1.88 | |
WRN helicase (MSI-high cancers) 3 cancers with incidence and prevalence data | 0 | 0 | 2 | 287k (235k to 339k) | 1.74 | |
CD47 2 cancers with incidence and prevalence data | 0 | 2 | 52 | 289k (205k to 374k) | 1.73 | |
ATR 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 1 | 39 | 116k (63k to 168k) | 1.73* | |
DLL3 2 cancers with incidence and prevalence data | 1 | 2 | 51 | 536k (382k to 690k) | 1.68 | |
HIF-2α 1 cancer with incidence and prevalence data | 1 | 0 | 34 | 127k (94k to 159k) | 1.58 | |
Progesterone receptor (PGR) 1 cancer with incidence and prevalence data | 4 | 0 | 97 | 269k (154k to 383k) | 1.49 | |
B7-H3 2 cancers with incidence and prevalence data | 0 | 4 | 40 | 515k (350k to 680k) | 1.36 | |
BCL-2 2 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 2 | 0 | 608 | 149k (88k to 211k) | 1.34* | |
NF1 (neurofibromin) 1 cancer with incidence and prevalence data | 1 | 0 | 0 | 151k (101k to 202k) | 1.32 | |
PRMT5 (MTAP-deleted cancers) 4 cancers with incidence and prevalence data | 0 | 1 | 16 | 381k (328k to 435k) | 1.31 | |
STK11 2 cancers with incidence and prevalence data | 1 | 0 | 0 | 245k (176k to 314k) | 1.22 | |
CD70 2 cancers with incidence and prevalence data | 0 | 0 | 4 | 174k (114k to 234k) | 1.15 | |
PIK3CA / PI3K-alpha 10 cancers with incidence and prevalence data | 5 | 2 | 206 | 1.2m (635k to 1.7m) | 1.02 | |
PTEN 3 cancers with incidence and prevalence data | 1 | 0 | 0 | 200k (78k to 323k) | 1 | |
Glypican-3 1 cancer with incidence and prevalence data | 0 | 0 | 2 | 311k (221k to 401k) | 0.96 | |
ROR1 3 cancers with incidence and prevalence data | 0 | 1 | 11 | 217k (112k to 321k) | 0.92 | |
MAGE-A4 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 2 | 0 | 2 | 379k (253k to 504k) | 0.79* | |
Aromatase (CYP19A1) 1 cancer with incidence and prevalence data | 2 | 0 | 621 | 275k (166k to 383k) | 0.73 | |
Folate receptor alpha 3 cancers with incidence and prevalence data | 3 | 4 | 57 | 1.3m (1.0m to 1.6m) | 0.7 | |
CDH6 2 cancers with incidence and prevalence data | 0 | 1 | 9 | 299k (217k to 381k) | 0.67 | |
HER3 4 cancers with incidence and prevalence data | 3 | 3 | 418 | 1.6m (1.2m to 2.0m) | 0.63 | |
KRAS 22 cancers with incidence and prevalence data | 13 | 7 | 177 | 5.3m (4.1m to 6.5m) | 0.6 | |
FAP 3 cancers with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 0 | 0 | 5 | 1.1m (890k to 1.4m) | 0.44* | |
Smoothened (hedgehog pathway) 1 cancer with incidence and prevalence data · partial: 1 without a GLOBOCAN estimate | 3 | 1 | 109 | 968k (968k to 968k) | 0.41* | |
Mesothelin 3 cancers with incidence and prevalence data | 0 | 0 | 7 | 587k (498k to 677k) | 0.34 | |
EpCAM 3 cancers with incidence and prevalence data | 1 | 1 | 19 | 1.8m (1.5m to 2.1m) | 0.28 | |
CEACAM5 3 cancers with incidence and prevalence data | 0 | 3 | 24 | 1.4m (1.1m to 1.8m) | 0.28 | |
TP53 14 cancers with incidence and prevalence data | 3 | 1 | 177 | 5.0m (3.9m to 6.2m) | 0.24 | |
| 12 | 7 | 553 | no incidence or prevalence data | n/a | ||
| 4 | 2 | 1,175 | no incidence or prevalence data | n/a | ||
| 4 | 1 | 303 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 4 | 0 | 614 | no incidence or prevalence data | n/a | ||
| 5 | 0 | 427 | no incidence or prevalence data | n/a | ||
| 0 | 3 | 38 | no incidence or prevalence data | n/a | ||
| 3 | 2 | 136 | no incidence or prevalence data | n/a | ||
| 3 | 1 | 27 | no incidence or prevalence data | n/a | ||
| 1 | 1 | 34 | no incidence or prevalence data | n/a | ||
| 0 | 2 | 7 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 7 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 8 | no incidence or prevalence data | n/a | ||
| 4 | 0 | 5,854 | no incidence or prevalence data | n/a | ||
| 3 | 1 | 1,584 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 1,958 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 343 | no incidence or prevalence data | n/a | ||
| 1 | 1 | 39 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 51 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 165 | no incidence or prevalence data | n/a | ||
| 2 | 1 | 1,215 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 393 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 2 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 420 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 3 | 0 | 144 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 132 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 8 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 158 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 52 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 5 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 204 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 22 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 1 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 93 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 8 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 120 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 3 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 60 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 249 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 112 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 5 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 1,215 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 207 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 3 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 2 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 2 | no incidence or prevalence data | n/a | ||
| 2 | 0 | 102 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 10 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 5 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 1 | 0 | 42 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 1 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 2 | no incidence or prevalence data | n/a | ||
| 0 | 1 | 1 | no incidence or prevalence data | n/a | ||
| 0 | 0 | 0 | no incidence or prevalence data | n/a |
* Partial population: one or more of the target’s cancers (sarcoma, GIST, neuroendocrine tumours, neuroblastoma) has no GLOBOCAN site estimate and is excluded from the denominator, so the index is inflated. Read those rows as “crowded in the cancers we can count”.
crowding = active assets / (addressable patients per year / 100,000)
active assets = corpus products aimed at the target, excluding
negative, withdrawn and historic
addressable/year = sum over cancers with a prevalence figure of
GLOBOCAN incidence (world) x subtype share
x prevalence x first setting share, midpointThe population term is how many people a treatment could reach, run for the world with the broadest setting. Targets whose cancers have no GLOBOCAN estimate (sarcoma, neuroendocrine tumours) or no parseable prevalence get no index, not a zero.
A high index means many programmes per patient: TROP2, HER2 and PD-1 crowding is real and shows up here. It does not measure quality, differentiation or the odds any one asset wins, and it counts only what is in this corpus, so thinly covered targets look less crowded than they are. Registry study counts include combination trials under each product named, so they overstate distinct trials.
Statuses come from product records (checked on the date each product record was last reviewed); registry counts were fetched 2026-11-09.